Immutep Announces Upcoming Poster Presentations at CTOS 2026 and ESMO Immuno-Oncology & Advanced Therapies Congress 2026 SYDNEY, AUSTRALIA – November 5, 2026 — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy company targeting cancer...
Upcoming Poster Presentations at CTOS and ESMO IO 2026
Filed with ASX · · 2 pages · English
Release
Story so far
- Translational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025
- EFTISARC-NEO Phase II results presented at CTOS 2025
- Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025
Earlier from Immutep
- Immutep Quarterly Activities Report and Appendix 4C
- Immutep Receives A$2.16 million French R&D Tax Incentive
- Notice of Annual General Meeting/Proxy Form
- Appendix 4G and Corporate Governance Statement
- Annual Report to shareholders
Later from Immutep
- IMP761 Late-Breaking Abstract at ACR shows T-Cell Inhibition
- IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses
- EFTISARC-NEO Survival Data reported in CTOS 2026 Abstract
- Immutep Expands US Patents for Efti Combination Therapies
- Immutep Announces Release of CTOS 2026 Abstract Reporting First Survival Data from EFTISARC-NEO
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep